Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing treatments for cancer and other serious diseases,
today announced that it will present at the third annual LD Micro Virtual
Conference at 1:40 p.m. EST on Wednesday, March 4. Genprex’s Chairman and Chief
Executive Officer, Rodney Varner, will lead the company’s presentation and
answer questions from investors. “We are delighted to be hosting our third
virtual event in order to showcase some of the truly unique names in micro-cap,”
LD Micro President Chris Lahiji said in the news release. “There are many
people and companies who are unable to attend our live events due to any number
of reasons, so we are happy to offer an additional way for companies to present
to investors without taking a lot of time out of their day-to-day operations.
While virtual events will never replace the experience of sitting in the same
room as other humans, it is a great format for updating the investor community
and getting increased exposure.”
To access the live presentation, visit http://ibn.fm/1qpB5
To view the full press release, visit http://ibn.fm/gGvRM
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing treatments for cancer and other serious
diseases. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with cancer
and other serious diseases who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches for patients with cancer and other serious
diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy
for non-small cell lung cancer (“NSCLC”), uses the company’s unique,
proprietary platform which delivers cancer-fighting genes by encapsulating them
into nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. In January 2020, the FDA granted Fast Track
Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the
treatment of NSCLC. For more information, please visit the company’s website
at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
